A Phase 3 Randomized Controlled Open-label Multicenter Safety and Efficacy Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Age: Between 18 - 100 Years
Gender: Male or Female
In order to be eligible to take part in this trial, patients must meet the following criteria:
- Male or female patients 18 years or older
- Biopsy-proven AL amyloidosis with relapsed or refractory disease despite 1 or 2 prior therapies. Patients may be proteasome inhibitor-exposed or naive, but cannot be refractory to proteasome inhibitor therapy
For a full list of participation criteria, please visit ClinicalTrials.gov.
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required